Comprehensive Study Guide: Healthcare Systems, Value Assessment, and MedTech Innovation
Foundations of Health and Health Systems Theory
Historical Milestones in Public Health and Systems Development:
1842 (Edwin Chadwick): Published The Sanitary Condition of the Labouring Population, establishing the empirical causal link between infectious disease, environmental filth, defective drainage, and contaminated water supplies.
1854 (John Snow): Demonstrated cholera epidemiology during the Broad Street pump outbreak in Soho, London, introducing geospatial mapping and data-driven disease containment before germ theory was formally codified.
1883 (Otto von Bismarck): Instituted the first statutory national social health insurance framework in Imperial Germany, creating compulsory sickness funds (Krankenkassen) financed by shared employer-employee payroll contributions.
1948 (National Health Service & World Health Organization):
Founding of the UK National Health Service (NHS), establishing universal healthcare financed through general taxation and free at the point of delivery.
Ratification of the World Health Organization (WHO) Constitution, introducing a holistic conceptualization of health.
1978 (Declaration of Alma-Ata): International conference calling for "Health for All" by the year 2000, establishing comprehensive Primary Health Care (PHC) as the central operational pillar of national health systems.
2015 (United Nations Sustainable Development Goals): Target 3.8 formally adopted Universal Health Coverage (UHC) as an international priority, focusing on financial risk protection, equitable access to essential services, and safe, effective, affordable essential medicines and vaccines.
Theoretical Frameworks Defining Health:
Biomedical Model (Christopher Boorse, 1977):
Defines health as the absence of physiological pathology, disease, or mechanical impairment.
Emphasizes objective clinical parameters and statistical normality of functional organs.
Conceptual limitation: Fails to accommodate subjective well-being, functional adaptation, or asymptomatic pathology.
WHO Biopsychosocial Formulation (1948):
Verbatim definition: "A state of complete physical, mental and social well-being and not merely the absence of disease or infirmity."
Established the visionary inclusion of psychological stability and social cohesion alongside somatic integrity.
Conceptual limitation: Employs an idealized threshold (complete well-being) that renders almost the entire living human population technically "unwell," creating unrealistic system targets and medicalizing everyday adversity.
Dynamic Adaptation Model (Machteld Huber et al., 2011):
Verbatim definition: "The ability to adapt and to self-manage in the face of social, physical, and emotional challenges."
Reconceptualizes health from a static state to a dynamic adaptive capability, recognizing that individuals living with chronic illness or physical disability can maintain operational health through autonomy and functional coping.
Conceptual limitation: Difficult to quantify objectively for population-level health system scorecards.
Social Determinants and the Gradient of Health:
The "Causes of the Causes" (Göran Dahlgren and Margaret Whitehead, 1991):
Health outcomes are structured hierarchically through layered determinants:
Layer 1: Core biological traits (age, biological sex, genetic predispositions).
Layer 2: Individual lifestyle choices (tobacco use, dietary patterns, exercise, alcohol consumption).
Layer 3: Social and community networks (kinship bonds, peer support, mutual aid).
Layer 4: Living and working conditions (housing quality, employment conditions, educational attainment, food security, water, sanitation, and direct healthcare access).
Layer 5: Broad socioeconomic, cultural, and environmental macroeconomic environments.
The Social Gradient (Michael Marmot, The Health Gap, 2015):
Population health follows a continuous stepwise socioeconomic gradient: health status systematically improves with every successive step up the income, educational, and social ladder.
Clinical healthcare accounts for a minority share of modifiable population morbidity and mortality; systemic health is heavily generated by housing, economic equity, clean environments, and early childhood interventions.
Health System Versus Healthcare System (WHO World Health Report, 2000):
Health System: Encompasses all organizations, institutions, policies, and activities whose primary intent is to promote, restore, or maintain health (e.g., environmental regulations, sanitation infrastructure, tobacco excise taxation, seatbelt mandates, clean air initiatives).
Healthcare System: The subsector comprising organizations, institutions, physical capital, professional personnel, and financial flows dedicated specifically to delivering clinical diagnostic, preventive, therapeutic, and rehabilitative care (e.g., hospitals, general practices, clinical personnel, medical devices, pharmaceuticals, insurers, regulatory agencies).
The Five P Framework of Healthcare Stakeholders
Theoretical Foundation:
Developed from the healthcare value chain analysis of Lawton R. Burns (2002) (The Health Care Value Chain: Producers, Purchasers, and Providers) and formalized by Prof. Prashant Jha into the Five P Framework: Patients, Providers, Payers, Producers, and Policymakers.
Every clinical, financial, and regulatory decision in a national healthcare system represents a continuous multi-party negotiation among these five actors.
Actor Profiles, Core Objectives, and Metrics of Success:
Patient:
Core Role: Receives care, incurs out-of-pocket expenses, and increasingly co-produces health through self-management, wearable tracking, and shared treatment decisions.
Primary Desire: Rapid, clinically safe, convenient, and affordable healthcare.
Success Criteria: Quality of life, clinical outcomes, patient experience scores, low out-of-pocket burden.
Provider:
Core Role: Clinicians (physicians, nurses, allied health workers), primary care centers, tertiary academic medical centres, community pharmacies, and allied health facilities delivering care.
Primary Desire: Clinical operational autonomy, adequate physical/technological resources, sustainable workload, and competitive remuneration.
Success Criteria: Clinical diagnostic quality, patient throughput/activity volume, professional safety, institutional reputation, low staff burnout.
Payer:
Core Role: Institutions pooling financial risk and reimbursing care (e.g., national statutory health agencies like the NHS, social sickness funds, private commercial insurers, out-of-pocket household expenditures, corporate employers).
Primary Desire: Maximizing aggregate population health gain subject to hard budgetary caps.
Success Criteria: Cost-effectiveness, cost per quality-adjusted life year (), net budgetary impact, low claims ratio.
Producer:
Core Role: Commercial and academic developers manufacturing biopharmaceuticals, generics, diagnostic tools, physical medical equipment, digital platforms, and artificial intelligence.
Primary Desire: Global market access, rapid regulatory approval, premium pricing, intellectual property protection, and return on capital investment.
Success Criteria: Volume adoption, operating margins, time-to-reimbursement, patent lifespan.
Policymaker:
Core Role: Governmental entities, parliamentary committees, regional health authorities, public regulators, and health technology assessment (HTA) bodies (e.g., MHRA, NICE, FDA).
Primary Desire: Overall population health security, political stability, health equity, public electoral support, industrial economic growth.
Success Criteria: System-wide performance targets, mortality rates, cost inflation containment, public trust, legislative sustainability.
Structural Friction Between the Five Ps:
Producer Payer Tension:
Manufacturers demand premium reimbursement rates to offset upfront R&D expenditures and ensure profit margins, while statutory payers enforce price caps and cost-effectiveness thresholds to maintain public budgets.
Payer Provider Tension:
Payers enforce strict financial controls (e.g., capitation, diagnostic-related group (DRG) prospective tariffs, rigid block budgets, volume-capping targets), whereas providers seek autonomy, fee-for-service financial rewards, and clinical discretion.
Patient Payer Tension:
Patients demand unrestricted, state-funded access to cutting-edge or experimental treatments, while payers ration interventions across the whole population according to utilitarian cost-effectiveness constraints.
Provider Patient Tension:
Patients expect personalized attention, shared decision-making, and immediate access; providers are constrained by strict consultation times, clinical guidelines, and resource rationing, generating administrative friction and waiting queues.
Policymaker All Ps Tension:
Policymakers establish regulatory guidelines, statutory reimbursement floors, and market authorizations that constrain the operational autonomy and financial prospects of all other four stakeholders simultaneously.
Exemplar System Deadlock: The Orkambi Case Study (2016–2019):
Therapeutic Context: Orkambi (lumacaftor/ivacaftor), developed by Vertex Pharmaceuticals for cystic fibrosis patients homozygous for the F508del mutation in the CFTR gene.
June–July 2016 (Initial Appraisal): The National Institute for Health and Care Excellence (NICE) issued Technology Appraisal 398 (TA398), rejecting Orkambi for routine NHS funding. Vertex listed Orkambi at approximately per patient per year; NICE determined its marginal health benefits did not meet standard cost-effectiveness thresholds.
2016–2019 (Three-Year Deadlock):
Patients and Families: Formed public pressure groups (supported by the Cystic Fibrosis Trust), protested at Parliament, and presented petitions demanding access to a licensed therapy.
Producer (Vertex Pharmaceuticals): Maintained pricing stance, arguing that high prices were necessary to recoup intensive R&D investments in rare disease therapeutics.
Payer (NICE / NHS England): Refused to exceed standard cost-effectiveness caps without substantial price concessions, guarding limited tax-funded budgets against budget displacement.
Providers (Respiratory Clinicians): Trapped between ethical duties to patients and statutory prohibitions against prescribing unapproved high-cost drugs.
Policymakers (Members of Parliament and Health Ministers): Summoned executives to parliamentary select committee hearings, applying political pressure for commercial compromise.
October 2019 (Resolution): NHS England reached a commercial portfolio agreement with Vertex covering lumacaftor/ivacaftor alongside other pipeline CFTR modulators (Symkevi and future therapies), breaking a three-year access impasse.
Health System Performance Measurement and Value Assessment
Evolution of System Evaluation Frameworks:
The Triple Aim (Donald Berwick, Thomas Nolan, and John Whittington, 2008):
1. Improving the patient experience of care (including quality and satisfaction).
2. Improving the health of populations.
3. Reducing the per capita cost of healthcare.
The Quadruple Aim (Thomas Bodenheimer and Kevin Sikka, 2014):
Added a fourth dimension: Improving the work life and well-being of healthcare clinicians and staff, addressing clinical burnout, turnover, and administrative exhaustion.
The Quintuple Aim (Kedar Mate, Shantanu Nundy, and Lisa Cooper, 2022):
Added a fifth dimension: Advancing health equity, assessing whether healthcare interventions disproportionately fail or reach socially disadvantaged, marginalized, or geographically isolated populations.
Evaluation of a Digital Telehealth Platform Across the Quintuple Aim:
Scenario: Implementation of a remote patient management platform for Type 2 Diabetes Mellitus, allowing patients to monitor glycemic status from home while clinicians oversee cohorts via an integrated dashboard.
Patient Experience: Eliminates transit times and clinical waiting rooms; tracked via patient satisfaction survey scores.
Population Health: Algorithmic triage detects early deterioration; tracked via reductions in mean cohort glycated hemoglobin () levels.
Cost per Capita: Mitigates acute emergency room admissions; tracked via net health expenditure per patient per year.
Workforce Well-Being: Centralized cohort dashboard streamlines administrative documentation; tracked via clinician burnout indices and staff turnover rates.
Health Equity: Assesses technological divide barriers (e.g., individuals lacking smartphones, digital literacy, or broadband coverage); tracked via utilization and uptake stratified by geographic index of multiple deprivation.
Balanced Scorecards and Key Performance Indicators (KPIs):
Adapts Robert Kaplan and David Norton’s Balanced Scorecard framework (1992) to healthcare operations across four operational quadrants:
1. Clinical Quality: e.g., Healthcare-associated infection rates, 30-day readmissions.
2. Operational Flow: e.g., Mean time from emergency triage to physician consultation.
3. Financial Performance: e.g., Cost per patient bed-day, variance from allocated budget.
4. Stakeholder Satisfaction: e.g., Patient-reported experience measures, clinician retention rates.
Standard SMART KPI Construction (Robotic Surgical System Adoption Example):
Clinical Metric: Cut mean operative blood loss during radical prostatectomies by within .
Operational Metric: Shorten operative duration by for surgical teams post their initial learning curve of .
Financial Metric: Reduce mean post-operative length of stay from to within the first fiscal year.
Provider Satisfaction Metric: Ensure operating surgeons and theatre scrub nurses rate console ergonomics and usability at on validated assessment scales.
The Pathologies of Measurement:
Goodhart’s Law (Charles Goodhart, 1975): "When a measure becomes a target, it ceases to be a good measure."
System dysfunctions documented by Gwyn Bevan and Christopher Hood (2006):
Gaming: Strategic manipulation of institutional behavior to meet numerical thresholds without improving substantive care.
Target Tunneling: Total managerial focus on metrics that are measured, leading to active neglect of non-measured clinical domains (e.g., psychiatric care, social rehabilitation).
Administrative Burden: Excessive data collection diverting clinicians from direct patient interaction.
Unfair Attribution: Clinicians penalised for systemic structural failures beyond their direct operational control.
Empirical Impact of the NHS 4-Hour A&E Target (Gruber, Hoe, and Stoye, 2023):
Target mandated that (reduced to in 2010) of patients entering an Emergency Department must be discharged, admitted, or transferred within 4 hours.
Measurable clinical benefits: Produced an average reduction in emergency wait times and lowered mortality by for acute cohorts.
Systematic institutional distortions: More than of patient dispositions occurred specifically within the final prior to the 4-hour deadline; caused an approximate artificial increase in emergency inpatient admissions solely to "stop the clock" before incurring financial and regulatory penalties.
The Five Control Knobs of Health Sector Reform (Marc Roberts, William Hsiao, Peter Berman, and Michael Reich, 2004):
Policy Control Knobs (Interventions):
Financing: How financial resources are mobilized (general taxation, payroll taxes, private insurance, user fees).
Payment: How providers are reimbursed (fee-for-service, capitation, global budgets, per-diem rates, pay-for-performance).
Organization: How clinical delivery is structured and coordinated (hospital autonomy, vertical integration of primary/secondary care, public vs. private ownership).
Regulation: The legal and statutory constraints on pricing, licensing, accreditation, service scope, and technological uptake.
Behavior: Interventions shaping consumer and provider choices (public health education, financial co-pays, clinical practice guidelines).
Intermediate Performance Measures: Efficiency, Clinical Quality, Access.
Final Health System Goals: Population Health Status, Citizen Satisfaction, Financial Risk Protection.
Health Technology Assessment, the QALY, and the ICER:
The Quality-Adjusted Life Year ():
Quantifies disease burden and therapeutic benefit by integrating duration of life with quality of life into a single metric: *
Utility is measured on an interval scale where and .
Utilities below zero: Valuation sets (e.g., EuroQol EQ-5D-3L valuation derived by Paul Dolan, 1997) demonstrate that the general public rates specific health states characterized by severe intractable pain, total paralysis, and cognitive loss as worse than death, reaching values down to (the English EQ-5D-5L tariff bottoms out at ).
Incremental Cost-Effectiveness Ratio ():
Worked Clinical Example (Rheumatoid Arthritis Biologic):
Standard therapy costs , delivering .
Novel biologic costs , delivering .
Incremental cost: .
Incremental benefit: .
Calculation: .
Jurisdictional Threshold Variations:
NICE (England & Wales, through March 2026): Hard threshold historically fixed at .
NICE (from April 2026): Threshold adjusted upwards to , introduced in the context of bilateral UK–US trade negotiations.
Institute for Clinical and Economic Review (ICER, United States): Independent advisory body utilizing a range of ; not legally binding on commercial or state payers.
US Federal Medicare: Statutorily prohibited by law (reinforced in the Inflation Reduction Act of 2022) from using thresholds, preventing the formal devaluation of life extensions for elderly, chronically disabled, or terminally ill populations.
NICE Severity Modifiers (Introduced January 2022):
Replaced the historic End-of-Life criteria with explicit multipliers for proportional and absolute disease severity:
No Severity Multiplier (): Standard willingness-to-pay ceiling ().
Severe Disease Multiplier (): Adjusts the effective ceiling up to .
Very Severe Disease Multiplier (): Adjusts the effective ceiling up to .
Valuing Human Life Across Public Sectors:
Marginal Opportunity Cost to the NHS (Karl Claxton et al., 2015): Empirical health economics reveals that when the NHS is forced to spend extra budget, it displaces existing services at an average threshold of approximately . Funding any technology priced above displaces more health across other clinical wards than it generates for the recipient cohort.
NICE Routine Medicine Threshold (April 2026): .
UK HM Treasury Green Book Formulation: Applies an overarching economic social value benchmark of approximately (in 2020/21 prices) for macro policy appraisals.
UK Department for Transport (DfT TAG Unit A4.1): Values life via the "Value of Preventing a Statistical Fatality" (VPF), pegged at over (originating from 1997 economic baselines and uprated annually).
Formative Group Assessment: Healthcare System Review (7QQMM314)
Structural Parameters and Governance:
Group Composition: Self-selected teams of 6 to 7 students, integrating medicine, engineering, and business disciplines.
Target Entity: One assigned sovereign national health system chosen exclusively from the 19 individual member nations of the G20.
Selection Constraint: Allocations operate strictly on a first-come, first-served basis via an online portal closing on Thursday, 8 October 2026 at 15:30 Hrs. Supranational bodies (the European Union and the African Union) are strictly barred from selection.
Permitted Nations List:
Americas: Argentina, Brazil, Canada, Mexico, United States.
Eurasia: France, Germany, Italy, Russia, Turkey, United Kingdom.
Asia-Pacific: Australia, China, India, Indonesia, Japan, South Korea.
Middle East & Africa: Saudi Arabia, South Africa.
Level of Analysis: Must assess the system at national level. Federal states (e.g., US, Canada, Australia, Germany, India, Brazil) require analysis of constitutional divisions between federal and provincial/state responsibilities without narrowing focus to one region.
Consultancy Role, Horizons, and Time Distribution:
Professional Premise: Independent healthcare consultancy preparing an appraisal for the client national Ministry of Health prior to its next strategic planning cycle.
Presentation Time Window: Minimum 4 minutes 00 seconds; maximum 5 minutes 00 seconds. Presentations are formally stopped at 5 minutes; talks under 4 minutes incur severe grading penalties. Followed by up to 5 minutes of unmarked viva questions.
Time Horizon Distribution:
Past (~20% of presentation): Major founding legislation, structural historical inflection points, and performance changes across the prior 20 to 25 years.
Present (~50% of presentation): Current operations, financing, clinical infrastructure, and performance mapped through the Five Ps.
Future (~30% of presentation): Scrutiny of national strategy documents, realism of planned reforms, and 2 to 3 prioritized consultant recommendations.
Required Analytical Slides:
The Friction Map:
A dedicated, standalone diagram linking the Five Ps (Patients, Providers, Payers, Producers, Policymakers).
Must explicitly plot at least two specific, bidirectional tensions between distinct Ps.
Each friction must have a concise descriptive label detailing the structural tension and its tangible impact on Access, Quality, Cost, or Equity.
Must visually identify and justify the single friction evaluated as most damaging to the system.
The Performance Scorecard:
Modeled upon the Commonwealth Fund’s Mirror, Mirror 2024 assessment criteria.
Evaluates five standardized domains:
1. Access to Care (affordability and geographic/temporal availability).
2. Care Process (clinical safety, preventive emphasis, care coordination, patient engagement).
3. Efficiency (administrative transaction burden vs. health outcomes achieved per expenditure).
4. Equity (disparities across income strata, geographic zones, and demographics).
5. Health Outcomes (rates of amenable mortality, treatable diseases, life expectancy).
Mandatory Elements: Each criterion must receive a rating of Strong, Mixed, or Weak, accompanied by one specific, dated empirical metric and an indicative trend arrow (Improving, Stable, or Worsening).
The Six Evaluative Questions:
Question 1: What is the friction between the Five Ps, and how does it compromise system efficiency, equity, or quality?
Question 2: What is the overall strategic ambition of the healthcare system according to official vision and policy documents, and how does this match empirical reality?
Question 3: What is the epidemiological state of health in the nation, and do subjective patient satisfaction ratings correlate with objective survival outcomes?
Question 4: Do patients experience timely, appropriate access to care, or do cost, geographic distance, and waiting queues generate unmet need?
Question 5: Does the system deliver equitable care, or are outcomes split by geographic territory, socioeconomic class, and demographic status?
Question 6: What governance mechanisms (e.g., resource allocation formulas, national quality standards, universal insurance mandates) harmonize clinical quality across provincial divisions, and do they work?
Submission Logistics, AI Policy, and Academic Integrity:
Deadline: Wednesday, 21 October 2026, precisely at 10:00 AM on KEATS.
Presentation Date: In-person workshop, 21 October 2026.
File Upload Protocol: Single PDF slide deck labeled
7QQMM314_[Country].pdf.Group Contribution Statement: A one-page document signed in blue ink by every group member specifying individual task breakdowns; individual grades may be altered if unequal distribution is evidenced.
Generative AI Policy: King's College London "Limited/Selective" tier applies. Permitted solely for brainstorming and structural ideation; data collection and analysis must be human-verified. A formal AI declaration statement must occupy the terminal slide.
Referencing Standard: Full King's Harvard referencing style, requiring short citations on each slide and comprehensive bibliographic listings on the final slides.
Primary Data Sources: Global Burden of Disease (IHME GBD Compare), WHO Global Health Expenditure Database (GHED), OECD Health Statistics, European Observatory on Health Systems and Policies, Commonwealth Fund Profiles.
Marking Criteria Weightings:
Criterion A: Five P Analysis ()
Criterion B: System Evaluation and Frictions ()
Criterion C: Consultant's Verdict and Time Horizons ()
Criterion D: Evidence Rigor and Sources ()
Criterion E: Communication, Slide Design, and Teamwork ()
Criterion F: Punctuality and Timing Adherence within 4 to 5 minutes ()
MSc MedTech Innovation and Entrepreneurship Programme Architecture
Curricular Structure:
Master of Science framework: 1 Integrated Academic Journey, 2 Interlocking Modules, 3 Semesters.
Module 314: MedTech Innovation, Ideation, Design, and Research Methods (delivering specific technical MedTech competencies and transferable translational skills).
Module 313: Research & Dissertation (providing the translational vehicle where skills developed in 314 are applied to a student-led research venture).
The 5D Pedagogical Model:
D1 — Discover: Broad health system exploration, epidemiology, clinical uncoupling points, and intellectual property landscape.
D2 — Define: Need specification, market sizing, ethical data governance, and stakeholder scoping.
D3 — Design: Processing data through synthesis, debate, human-centered co-design, and iterative technical prototyping.
D4 — Develop: Translational project planning, regulatory alignment, milestone allocation, and risk management.
D5 — Deploy: Commercial pitching, investment capital acquisition, stakeholder negotiation, and clinical adoption.
Curricular Progression by Semester:
Semester 1 (September to December) — Foundations & Teams:
Core Pillars Introduced: Health Systems, Evidence, Venture, People & Pitch.
5D Stages Active: Discover (D1) and Define (D2).
Core Skills Acquired:
Understanding Health & Health Systems: Analyzing healthcare delivery mechanisms, structural failures, and financial incentives.
Intellectual Property: Institutional IP ownership criteria in academic environments, patent landscapes, and defensive IP strategies.
Research Methods: Qualitative versus quantitative approaches, data integrity, and eliminating observational bias.
Ethics: Safe data governance, ethical study design, and formal institutional ethics approval via the King's REMAS framework.
Team Building: Interdisciplinary collaboration across clinical, engineering, and commercial skill sets.
Market Research: Differentiating peer-reviewed scientific literature from grey industry data; primary vs. secondary research; identifying market whitespace.
Human-Centred Design (HCD): User psychology, patient/clinician co-design, usability testing, and prototype iteration.
Milestones & Assessments: Formative 1 (Country Health Systems Review); Summative 1 (Applying the 5D Model: Initial Venture Pitch); Final Team Formation.
Competency Profile by December: Ability to deconstruct healthcare systems, isolate clinical failures, design ethical research, size target markets, and align interdisciplinary project teams.
Semester 2 (January to April) — Evidence & Execution:
5D Stages Active: Design (D3), Develop (D4), and Deploy (D5).
Core Skills Acquired:
Scientific Paper Reading: Deconstructing clinical evidence, statistical validity, and trial design.
Developing Insights: Thematic coding and qualitative extraction from raw stakeholder and patient interviews.
Academic Writing: Professional manuscript framing and critical literature synthesis.
Project Management: Milestone generation, critical path allocation, budget tracking, and risk mitigation.
Fundraising: Venture financing pathways, non-dilutive grant capital, angel/seed investment, and stakeholder pitching.
Storytelling & Communication: Structural narrative building, message retention, and audience tailoring.
Commercial Negotiations: Strategic negotiation tactics, defensible term sheets, and win-win partnership development.
Milestones & Assessments: Summative 2 (Narrative Review: System Gaps); Summative 3 (Costed, Milestone-Driven Project Plan).
Competency Profile by April: Ability to define a verified clinical problem, synthesize existing literature, formulate a fully costed development plan, and deliver pitches to secure financial backing.
Semester 3 (May to August) — Research & Dissertation:
Direct convergence of all prior curricular streams into Module 313.
Core Milestones:
May to July: Primary data collection and empirical testing.
June to July: Translational research ideation (refining the healthcare problem into a formal research thesis question).
July to August: Business Plan drafting (grounded in empirical field evidence).
July to August: Iterative product refinement (V2 prototyping based on stakeholder user feedback).
August: Final dissertation synthesis, refinement, and academic submission.
Competency Profile by August: Full independence in transforming an identified health system failure into a defensible research thesis, conducting primary research, drafting a commercial business model, and producing a complete academic dissertation.
Questions & Discussion
Case-Based Deliberations on the Nature of Health:
Case 1: The Paralympic Athlete:
Scenario: A 30-year-old competitive swimmer who uses a wheelchair for mobility, training 20 hours per week.
Biomedical Model Verdict: Contested or diseased/impaired due to structural spinal cord pathology.
1948 WHO Model Verdict: Strictly "not healthy" due to incomplete physical functioning.
2011 Huber Adaptation Model Verdict: "Healthy," demonstrating optimal social adaptation, physical conditioning, and functional self-management.
Case 2: Controlled Endocrine Disease:
Scenario: A 45-year-old professional with well-controlled Type 1 Diabetes Mellitus, working full-time and rarely thinking about the condition.
Biomedical Model Verdict: "Not healthy" due to permanent autoimmune pancreatic beta-cell destruction.
1948 WHO Model Verdict: Ambiguous; manages normal social life but relies on exogenous endocrine therapy.
2011 Huber Adaptation Model Verdict: "Healthy," having fully adapted to lifestyle requirements and maintaining independent self-management.
Case 3: Asymptomatic Silent Pathology:
Scenario: A 55-year-old who feels energetic and runs weekly, but has severe, undiagnosed systemic hypertension.
Biomedical Model Verdict: "Not healthy" due to objective vascular pathology.
1948 WHO Model Verdict: Subjectively feels healthy, yet harbors high cardiovascular risk.
2011 Huber Adaptation Model Verdict: "Unhealthy/Compromised," as the individual cannot self-manage or adapt to a biological threat they are unaware of.
Case 4: Socially Isolated Geriatric Individual:
Scenario: A 72-year-old physically fit widower with no medical diagnoses, living in total social isolation without meaningful human conversation for two weeks.
Biomedical Model Verdict: "Healthy," showing complete absence of biological disease.
1948 WHO Model Verdict: "Not healthy" due to severe deficits in the social well-being domain.
2011 Huber Adaptation Model Verdict: Dependent on whether the individual has adapted or is deteriorating emotionally into depression and frailty.
Stakeholder Role-Play: The Diabetes Telehealth Platform:
Scenario: A MedTech company proposes an integrated remote monitoring platform to the NHS where patients track blood glucose from home while clinicians monitor cohorts via a dashboard.
Patient Perspective: Prioritizes elimination of travel costs and clinic wait times; requires intuitive, non-stigmatizing hardware and data transparency.
Provider Perspective: Demands interoperability with existing electronic health records (EHRs); concerns focus on medicolegal liability for unread alert backlogs and dashboard administrative overload.
Payer Perspective: Requires demonstrated reductions in emergency admissions per cohort per annum () to justify software licensing costs.
Producer Perspective: Requires high multi-year recurring SaaS subscription fees, data asset monetization, and rapid regional commissioning pathways.
Policymaker Perspective: Requires digital inclusion guarantees ensuring underprivileged, non-English-speaking, or elderly populations lacking digital literacy are not excluded.
The Immunotherapy Decision Problem:
Clinical Appraisal Parameters:
Current Standard of Care (Chemotherapy): Costs per patient; yields .
Novel Intervention (Immunotherapy): Costs per patient; yields .
Baseline Willingness-to-Pay Ceiling: Set at .
Mathematical Determination:
Incremental Financial Cost: .
Incremental Health Benefit: .
Baseline ICER: .
Baseline Recommendation: At a threshold, the therapy is rejected because the ICER () exceeds the maximum willingness-to-pay ceiling.
Severity Multiplier Application:
Under NICE’s 2022 Severity Modifiers, if the condition meets the criteria for Severe Disease (), the quality-adjusted benefit is weighted as , generating an effective ICER of: Verdict: Funded under a ceiling, but rejected under NICE's traditional standard upper limit of .
If the condition qualifies as Very Severe Disease (), the benefit is weighted as , generating an effective ICER of: Verdict: Funded without reservation, falling comfortably within NICE’s baseline statutory range.
Formative Assessment Frequently Asked Questions:
Can a group select a health system covered during foundational lectures (e.g., the UK, US, or India)? Yes, but the group must provide comprehensive analysis that goes well beyond introductory lecture concepts.
Can international students select their home nation? Yes. Native knowledge and contextual familiarity are beneficial, particularly regarding local media perception of Producer dependencies; however, all assertions must be substantiated with published empirical data.
Can the European Union or African Union be selected? No. While both sit as members of the G20, neither is a sovereign nation running a unified healthcare system.
Must each of the Five Ps receive identical presentation time? No. Every P must be introduced, but time should be weighted toward the Ps where the national system faces its most distinct structural challenges.
What qualifies as a valid population condition under the Patient domain? Any major pathology, chronic disease, injury category, or quantified behavioral risk factor (e.g., ischemic heart disease, stroke, major depressive disorder, road traffic trauma, obesity, tobacco dependence) that ranks at the top of national DALYs, mortality, or prevalence tables according to the Global Burden of Disease study.
Is omission of an individual evaluative question permitted if time runs short? No. All six evaluative questions must be addressed. Minor questions can be covered with a single, well-evidenced sentence, while the friction map must remain the central analytical focus.
Can the Friction Map and Performance Scorecard share a single visual slide? No. They must remain on separate slides to ensure clarity during the rapid presentation.
What should a group do if a country is excluded from the Commonwealth Fund's Mirror, Mirror 2024 report? Most G20 nations are not covered in Mirror, Mirror. Groups must construct their scorecard using the five standardized criteria, sourcing empirical data from the WHO, OECD, European Observatory, or national ministries.
What should be done if data for a particular scorecard criterion is absent or conflicting? Data gaps must be explicitly stated as analytical findings rather than masked with conjecture. Where estimates vary across databases, select a single consistent international baseline (e.g., WHO GHED) and note the discrepancy if it alters system interpretation.